Immune Tolerance Induction to Factor IX through B Cell Gene Transfer: TLR9 Signaling Delineates between Tolerogenic and Immunogenic B Cells

Molecular Therapy

Volumn 22, Issue 6, 2014, Pages 1139-1150

  Wang, Xiaomei ^a   Moghimi, Babak ^b   Zolotukhin, Irene ^a   Morel, Laurence M ^a   Cao, Ou ^a   Herzog, Roland W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BLOOD CLOTTING FACTOR 9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; INTERFERON; INTERLEUKIN 6; OLIGONUCLEOTIDE; PLASMID DNA; PLASMID VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 9; RETROVIRUS VECTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; IMMUNOGLOBULIN G; TLR9 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL BASED GENE THERAPY; CONTROLLED STUDY; DNA MODIFICATION; F9 GENE; FUSION GENE; GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE TRANSFER; HEMOPHILIA B; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; ANAPHYLAXIS; ANIMAL TISSUE; BLAST CELL; CELL THERAPY; CELL TRANSPLANTATION; CPG ISLAND; DESENSITIZATION; GENE CASSETTE; IMMUNOGENICITY; INTRACELLULAR SIGNALING; PLASMID; PROTEIN EXPRESSION; RETROVIRUS; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROCEDURES; RETROVIRIDAE; SPLEEN;

ANIMALIA; MURINAE;

ADOPTIVE TRANSFER; ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FACTOR IX; GENETIC THERAPY; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; MICE; MICE, INBRED C57BL; PLASMIDS; RETROVIRIDAE; SIGNAL TRANSDUCTION; SPLEEN; TOLL-LIKE RECEPTOR 9; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84902146823     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.43     Document Type: Article

References (50)

1. DiMichele, D (2007). Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 138: 305-315.
2. Castaman, G, Giacomelli, SH, Caccia, S, Riccardi, F, Rossetti, G, Dragani, A et al. (2014). The spectrum of factor XI deficiency in Italy. Haemophilia 20: 106-113.
3. DiMichele, DM (2012). Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 159: 123-134.
4. Anderton, SM and Fillatreau, S (2008). Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 4: 657-666.
5. Eynon, EE and Parker, DC (1992). Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175: 131-138.
6. Fillatreau, S, Sweenie, CH, McGeachy, MJ, Gray, D and Anderton, SM (2002). B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944-950. (Pubitemid 35154008)
7. Su, Y, Carey, G, Maric, M and Scott, DW (2008). B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathway. J Immunol 181: 1153-1160.
8. Scott, DW, Zhang, AH and Su, Y (2012). B-cell based gene therapy for autoimmune diseases. Infect Disord Drug Targets 12: 241-247.
9. Scott, DW (2010). Gene therapy for immunological tolerance: using 'transgenic' B cells to treat inhibitor formation. Haemophilia 16: 89-94.
10. Verma, D, Moghimi, B, LoDuca, PA, Singh, HD, Hoffman, BE, Herzog, RW et al. (2010). Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA 107: 7101-7106.
11. Moghimi, B, Zolotukhin, I, Sack, BK, Herzog, RW and Cao, O (2011). High Efficiency Ex Vivo Gene Transfer to Primary Murine B Cells Using Plasmid or Viral Vectors. J Genet Syndr Gene Ther 2: 103.
12. Sabatino, DE, Nichols, TC, Merricks, E, Bellinger, DA, Herzog, RW and Monahan, PE (2012). Animal models of hemophilia. Prog Mol Biol Transl Sci 105: 151-209.
13. Jordan, JM, Woods, ME, Olano, J and Walker, DH (2008). The absence of Toll-like receptor 4 signaling in C3H/HeJ mice predisposes them to overwhelming rickettsial infection and decreased protective Th1 responses. Infect Immun 76: 3717-3724.
14. Knezevic, J, Pavlinic, D, Rose, WA 2nd, Leifer, CA, Bendelja, K, Gabrilovac, J et al. (2012). Heterozygous carriage of a dysfunctional Toll-like receptor 9 allele affects CpG oligonucleotide responses in B cells. J Biol Chem 287: 24544-24553.
15. Crampton, SP, Voynova, E and Bolland, S (2010). Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci 1183: 58-68.
16. Gay, NJ, Gangloff, M and Weber, AN (2006). Toll-like receptors as molecular switches. Nat Rev Immunol 6: 693-698. (Pubitemid 44298218)
17. Monie, TP, Moncrieffe, MC and Gay, NJ (2009). Structure and regulation of cytoplasmic adapter proteins involved in innate immune signaling. Immunol Rev 227: 161-175.
18. Sasai, M, Linehan, MM and Iwasaki, A (2010). Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329: 1530-1534.
19. Elder, ME, Nayak, S, Collins, SW, Lawson, LA, Kelley, JS, Herzog, RW et al. (2013). B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 163: 847-54.e1.
20. Sack, BK, Merchant, S, Markusic, DM, Nathwani, AC, Davidoff, AM, Byrne, BJ et al. (2012). Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS ONE 7: e37671.
21. Zhang, AH, Skupsky, J and Scott, DW (2011). Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood 117: 2223-2226.
22. Rossi, RJ, Jackson, BM, Zhang, AH and Scott, DW (2012). Tolerance induction via B-cell delivered gene therapy. Methods Mol Biol 900: 471-487.
23. Lei, TC and Scott, DW (2005). Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 105: 4865-4870. (Pubitemid 40812408)
24. El-Amine, M, Melo, M, Kang, Y, Nguyen, H, Qian, J and Scott, DW (2000). Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol 165: 5631-5636.
25. Skupsky, J, Zhang, AH, Su, Y and Scott, DW (2010). B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol Ther 18: 1527-1535.
26. Cao, O, Armstrong, E, Schlachterman, A, Wang, L, Okita, DK, Conti-Fine, B et al. (2006). Immune deviation by mucosal antigen administration suppresses genetransfer-induced inhibitor formation to factor IX. Blood 108: 480-486. (Pubitemid 44061345)
27. Cao, O, Hoffman, BE, Moghimi, B, Nayak, S, Cooper, M, Zhou, S et al. (2009). Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 17: 1733-1742.
28. Matheu, MP, Su, Y, Greenberg, ML, Blanc, CA, Parker, I, Scott, DW et al. (2012). Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance. Proc Natl Acad Sci USA 109: E1258-E1266.
29. Cousens, LP, Tassone, R, Mazer, BD, Ramachandiran, V, Scott, DW and De Groot, AS (2013). Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 12: 436-443.
30. Allacher, P, Baumgartner, CK, Pordes, AG, Ahmad, RU, Schwarz, HP and Reipert, BM (2011). Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9. Blood 117: 259-267.
31. Pordes, AG, Baumgartner, CK, Allacher, P, Ahmad, RU, Weiller, M, Schiviz, AN et al. (2011). T cell-independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist. Blood 118: 3154-3162.
32. Ahangarani, RR, Janssens, W, Carlier, V, Vanderelst, L, Vandendriessche, T, Chuah, M et al. (2011). Retroviral vectors induce epigenetic chromatin modifications and IL-10 production in transduced B cells via activation of toll-like receptor 2. Mol Ther 19: 711-722.
33. Ahangarani, RR, Janssens, W, VanderElst, L, Carlier, V, VandenDriessche, T, Chuah, M et al. (2009). In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. J Immunol 183: 8232-8243.
34. Su, Y, Zhang, AH, Noben-Trauth, N and Scott, DW (2011). B-Cell Gene Therapy for Tolerance Induction: Host but Not Donor B-Cell Derived IL-10 is Necessary for Tolerance. Front Microbiol 2: 154.
35. Medzhitov, R (2001). Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145. (Pubitemid 33741967)
36. Doronin, K, Flatt, JW, Di Paolo, NC, Khare, R, Kalyuzhniy, O, Acchione, M et al. (2012). Coagulation factor X activates innate immunity to human species C adenovirus. Science 338: 795-798.
37. Herzog, RW and Ostrov, DA (2012). Immunology. A decorated virus cannot hide. Science 338: 748-749.
38. Hemmi, H, Takeuchi, O, Kawai, T, Kaisho, T, Sato, S, Sanjo, H et al. (2000). A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745. (Pubitemid 32015992)
39. Honda, K, Yanai, H, Negishi, H, Asagiri, M, Sato, M, Mizutani, T et al. (2005). IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777. (Pubitemid 44739521)
40. Takaoka, A, Yanai, H, Kondo, S, Duncan, G, Negishi, H, Mizutani, T et al. (2005). Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434: 243-249. (Pubitemid 40388058)
41. Iwasaki, A and Medzhitov, R (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995. (Pubitemid 41057715)
42. Le Bon, A, Schiavoni, G, D'Agostino, G, Gresser, I, Belardelli, F and Tough, DF (2001). Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470. (Pubitemid 32441598)
43. Yang, Y, Huang, CT, Huang, X and Pardoll, DM (2004). Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5: 508-515. (Pubitemid 38660463)
44. Pasare, C and Medzhitov, R (2003). Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036. (Pubitemid 36222922)
45. Moghimi, B, Sack, BK, Nayak, S, Markusic, DM, Mah, CS and Herzog, RW (2011). Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 9: 1524-1533.
46. Kang, Y, Melo, M, Deng, E, Tisch, R, El-Amine, M and Scott, DW (1999). Induction of hyporesponsiveness to intact foreign protein via retroviralmediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci USA 96: 8609-8614. (Pubitemid 29354839)
47. Martino, AT, Suzuki, M, Markusic, DM, Zolotukhin, I, Ryals, RC, Moghimi, B et al. (2011). The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117: 6459-6468.
48. Wang, XM, Kim, HP, Nakahira, K, Ryter, SW and Choi, AM (2009). The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J Immunol 182: 3809-3818.
49. Mingozzi, F, Liu, YL, Dobrzynski, E, Kaufhold, A, Liu, JH, Wang, Y et al. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111: 1347-1356. (Pubitemid 36554705)
50. Markusic, DM, Hoffman, BE, Perrin, GQ, Nayak, S, Wang, X, LoDuca, PA et al. (2013). Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 5: 1698-1709.